
|Articles|July 27, 2020
Montrium’s eTMF Connect Solution Used in Global Phase III PTSD Study
Advertisement
Montrium, a provider of cloud-based software solutions for the life sciences, announced its eTMF Connect trial master file solution is being used in a Phase III global post-traumatic stress disorder (PTSD) trial. The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research organization is advancing from its MAPP1, the first study carried out in Phase III, to a global confirmatory MAPP2 study to assess the safety and efficacy of MDMA-assisted psychotherapy for patients with PTSD.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results
2
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
3
Applying AI to Automate Workflows Without Disrupting Sites
4
Measuring Whether Site Support Investments Are Actually Working
5




